Hospital
W.A. Foote Memorial Hospital, INC.
W.A. Foote Memorial Hospital, INC. was paid $39.86M by Medicaid between Jan 2018 and Jul 2024, across 408 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 21% of everything it billed.
33Billing provider infoW.A. FOOTE MEMORIAL HOSPITAL, INC.
JACKSON, MI 49201
JACKSON, MI 49201
33aNPI1265528939assigned 10/04/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$39.86M
24GClaims1,150,407
24DCodes billed408
24AFirst – last monthJan 2018 – Jul 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#31 of 86
Median peer was paid$21.55M
This provider vs. median1.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 205,479 | $6.99M | |
| 2019 | 211,332 | $6.60M | |
| 2020 | 156,638 | $4.87M | |
| 2021 | 175,987 | $6.45M | |
| 2022 | 191,427 | $6.92M | |
| 2023 | 150,936 | $5.68M | |
| 2024incomplete | 58,608 | $2.35M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 21% | 192,188 | 148,540 | $8.18M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 34,836 | 31,261 | $6.06M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 34,220 | 31,782 | $4.92M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.2% | 24,991 | 22,665 | $3.65M |
| G0378 | Hospital observation service, per hour | 8.9% | 4,034 | 3,843 | $3.55M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.1% | 23,701 | 20,569 | $845K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.9% | 5,312 | 5,186 | $751K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.3% | 26,979 | 9,196 | $528K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 7,877 | 5,007 | $479K |
| 20610 | 1.1% | 3,398 | 2,603 | $450K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.1% | 2,871 | 1,642 | $435K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 5,678 | 5,508 | $331K |
396 more codes
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,037 | $323K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 17,308 | $304K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 20,528 | $285K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 7,851 | $259K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 5,312 | $256K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 17,913 | $234K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,967 | $227K |
| 97161 | <1% | 4,911 | $225K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,080 | $209K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 3,327 | $200K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 5,174 | $196K |
| 59025 | Fetal non-stress test | <1% | 2,328 | $183K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,923 | $178K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 886 | $178K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 8,330 | $171K |
| 76830 | Ultrasound, transvaginal | <1% | 3,838 | $166K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 2,571 | $161K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,351 | $160K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 2,680 | $159K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 2,689 | $158K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 2,590 | $154K |
| 62323 | <1% | 552 | $154K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,249 | $151K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 621 | $146K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 7,074 | $141K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 3,706 | $138K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 9,964 | $136K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 577 | $134K |
| 90837 | Psychotherapy session, about an hour | <1% | 2,222 | $131K |
| 93975 | <1% | 2,120 | $122K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 1,869 | $111K |
| 90670 | <1% | 2,056 | $110K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 394 | $106K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 21,848 | $105K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,313 | $104K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 2,031 | $100K |
| 76801 | <1% | 2,388 | $100K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 848 | $97K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,064 | $96K |
| 90677 | <1% | 411 | $94K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 4,018 | $88K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 193 | $87K |
| 97165 | <1% | 1,931 | $79K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 3,958 | $73K |
| Q3014 | Telehealth originating site facility fee | <1% | 4,646 | $73K |
| 93971 | <1% | 1,761 | $68K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 225 | $67K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 5,266 | $65K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 164 | $63K |
| 90686 | <1% | 4,887 | $63K | |
| 76536 | <1% | 1,202 | $62K | |
| 80061 | Lipid panel | <1% | 3,540 | $61K |
| 76770 | <1% | 1,486 | $57K | |
| 90651 | <1% | 724 | $57K | |
| 96367 | <1% | 1,931 | $57K | |
| 95811 | <1% | 110 | $53K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,947 | $52K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,430 | $52K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,278 | $51K |
| 76642 | <1% | 1,493 | $51K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,753 | $50K |
| G0008 | Administration of influenza virus vaccine | <1% | 5,298 | $48K |
| 90682 | <1% | 882 | $47K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,111 | $45K |
| 73564 | <1% | 2,480 | $43K | |
| 72110 | <1% | 1,891 | $40K | |
| 73630 | <1% | 6,026 | $39K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 955 | $36K |
| 86900 | <1% | 4,173 | $36K | |
| 93970 | <1% | 394 | $36K | |
| 72141 | <1% | 276 | $34K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,643 | $33K |
| 72100 | <1% | 1,594 | $32K | |
| 74018 | <1% | 2,150 | $31K | |
| 72050 | <1% | 981 | $31K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 210 | $31K |
| 93017 | <1% | 640 | $30K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 3,340 | $30K |
| 73610 | <1% | 4,404 | $26K | |
| 71250 | <1% | 557 | $26K | |
| 73130 | <1% | 4,887 | $25K | |
| 90750 | <1% | 174 | $25K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 2,089 | $25K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 24,976 | $24K |
| 64483 | <1% | 68 | $24K | |
| 73030 | <1% | 3,416 | $24K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 3,692 | $22K |
| 73110 | <1% | 3,271 | $21K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 395 | $20K |
| 73221 | <1% | 171 | $20K | |
| 80053 | Comprehensive metabolic panel | <1% | 27,030 | $20K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 905 | $20K |
| 71271 | <1% | 339 | $20K | |
| 73502 | <1% | 2,279 | $19K | |
| 97760 | <1% | 516 | $18K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,907 | $18K |
| 76882 | <1% | 435 | $17K | |
| 73140 | <1% | 2,282 | $17K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,491 | $17K |
| 90732 | <1% | 184 | $16K | |
| 10060 | <1% | 492 | $15K | |
| 73562 | <1% | 1,265 | $14K | |
| 70496 | <1% | 380 | $14K | |
| 73100 | <1% | 1,710 | $14K | |
| 94726 | <1% | 101 | $13K | |
| 73560 | <1% | 3,714 | $13K | |
| 73080 | <1% | 1,978 | $12K | |
| 70486 | <1% | 647 | $12K | |
| 77066 | Tomosynthesis, mammo | <1% | 209 | $12K |
| 91320 | <1% | 93 | $11K | |
| 90734 | <1% | 487 | $11K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,724 | $11K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 46,811 | $11K |
| G0009 | Administration of pneumococcal vaccine | <1% | 1,234 | $11K |
| 17110 | <1% | 814 | $11K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 79 | $10K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,940 | $10K |
| 0001A | <1% | 266 | $10K | |
| 92551 | <1% | 1,481 | $10K | |
| 20611 | <1% | 67 | $10K | |
| 0124A | <1% | 264 | $10K | |
| 72072 | <1% | 512 | $9K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 265 | $9K |
| 90716 | <1% | 380 | $9K | |
| 0054A | <1% | 253 | $9K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,167 | $8K |
| 0002A | <1% | 222 | $8K | |
| 11100 | <1% | 61 | $8K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,223 | $7K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 18 | $7K |
| 99406 | <1% | 466 | $7K | |
| 84702 | <1% | 7,554 | $7K | |
| 64450 | <1% | 55 | $6K | |
| 51798 | <1% | 1,845 | $6K | |
| 73590 | <1% | 1,296 | $6K | |
| 86780 | <1% | 920 | $6K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 551 | $6K |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 415 | $6K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 25,772 | $6K |
| 97162 | <1% | 171 | $6K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 516 | $5K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 467 | $5K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 571 | $5K |
| 77080 | <1% | 91 | $5K | |
| 0004A | <1% | 143 | $5K | |
| 85027 | <1% | 7,988 | $5K | |
| 90480 | <1% | 128 | $5K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,878 | $4K |
| 64615 | <1% | 36 | $4K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,656 | $4K |
| 73090 | <1% | 1,036 | $4K | |
| 87081 | <1% | 5,217 | $4K | |
| 76818 | <1% | 73 | $4K | |
| J7323 | Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose | <1% | 44 | $4K |
| 87631 | <1% | 1,456 | $4K | |
| 62321 | <1% | 13 | $4K | |
| 74022 | <1% | 446 | $4K | |
| 29125 | <1% | 789 | $3K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,702 | $3K |
| 29085 | <1% | 49 | $3K | |
| J7321 | Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | <1% | 70 | $3K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,126 | $3K |
| 73020 | <1% | 308 | $3K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,351 | $3K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 230 | $3K |
| 80074 | <1% | 195 | $3K | |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 631 | $3K |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 16 | $3K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 9,687 | $3K |
| 90620 | <1% | 29 | $3K | |
| 77065 | Tomosynthesis, mammo | <1% | 71 | $3K |
| 64400 | <1% | 29 | $3K | |
| 25600 | <1% | 27 | $3K | |
| 93880 | <1% | 27 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,267 | $3K |
| 99495 | <1% | 55 | $2K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 27 | $2K |
| 71101 | <1% | 267 | $2K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 13 | $2K |
| 87511 | <1% | 129 | $2K | |
| 87481 | <1% | 129 | $2K | |
| 93229 | <1% | 13 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,772 | $2K |
| 84439 | <1% | 1,090 | $2K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 125 | $2K |
| 72040 | <1% | 197 | $2K | |
| 97022 | <1% | 307 | $2K | |
| 85610 | <1% | 6,505 | $2K | |
| 95909 | <1% | 14 | $2K | |
| 82607 | <1% | 430 | $2K | |
| 99383 | <1% | 27 | $2K | |
| 86803 | <1% | 443 | $2K | |
| 87186 | <1% | 1,935 | $2K | |
| 73600 | <1% | 877 | $2K | |
| 82728 | <1% | 446 | $2K | |
| 87077 | <1% | 1,761 | $2K | |
| 20600 | <1% | 14 | $2K | |
| 70498 | <1% | 334 | $2K | |
| 29075 | <1% | 14 | $2K | |
| 72131 | <1% | 75 | $2K | |
| 95908 | <1% | 12 | $2K | |
| 20553 | <1% | 13 | $2K | |
| 81001 | <1% | 20,252 | $1K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 221 | $1K |
| 70470 | <1% | 14 | $1K | |
| 83735 | <1% | 8,939 | $1K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 109 | $1K |
| 97116 | <1% | 416 | $1K | |
| 93225 | <1% | 25 | $1K | |
| 20550 | <1% | 14 | $1K | |
| 87653 | <1% | 72 | $1K | |
| 31575 | <1% | 12 | $1K | |
| 98927 | <1% | 485 | $1K | |
| 82570 | <1% | 813 | $1K | |
| 93922 | <1% | 38 | $1K | |
| 83550 | <1% | 396 | $1K | |
| 69210 | <1% | 188 | $1K | |
| 87070 | <1% | 1,091 | $1K | |
| 83880 | <1% | 1,471 | $1K | |
| 97014 | <1% | 121 | $1K | |
| 11721 | <1% | 133 | $982.86 | |
| 0051A | <1% | 28 | $975.78 | |
| 83540 | <1% | 478 | $974.49 | |
| 86140 | <1% | 2,005 | $942.13 | |
| Q2036 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval) | <1% | 135 | $935.74 |
| 99384 | <1% | 13 | $918.45 | |
| 87340 | <1% | 405 | $913.85 | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 26 | $894.36 |
| 0052A | <1% | 23 | $863.19 | |
| 90658 | <1% | 49 | $832.84 | |
| 31231 | <1% | 12 | $799.50 | |
| 97035 | <1% | 164 | $761.25 | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 12 | $723.60 |
| 99386 | <1% | 12 | $721.49 | |
| 70491 | <1% | 12 | $717.47 | |
| 81025 | <1% | 12,741 | $660.81 | |
| 82248 | <1% | 8,771 | $654.70 | |
| 82043 | <1% | 344 | $612.30 | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 239 | $600.85 |
| 90744 | <1% | 67 | $575.08 | |
| 12001 | <1% | 540 | $562.95 | |
| G0451 | Development testing, with interpretation and report, per standardized instrument form | <1% | 30 | $537.60 |
| 73700 | <1% | 12 | $524.34 | |
| 83690 | <1% | 12,522 | $498.05 | |
| 86592 | <1% | 198 | $482.40 | |
| 81003 | <1% | 3,612 | $473.90 | |
| 85652 | <1% | 1,306 | $473.66 | |
| 87634 | <1% | 884 | $471.08 | |
| 87088 | <1% | 456 | $460.18 | |
| 82947 | <1% | 224 | $456.31 | |
| 90662 | <1% | 47 | $421.44 | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 16 | $381.76 |
| 96161 | <1% | 58 | $371.81 | |
| 36591 | <1% | 12 | $323.95 | |
| 86850 | <1% | 4,175 | $318.61 | |
| 11055 | <1% | 12 | $313.02 | |
| 87205 | <1% | 925 | $303.66 | |
| 82274 | <1% | 256 | $303.66 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,987 | $296.87 |
| 84146 | <1% | 32 | $292.77 | |
| 73552 | <1% | 77 | $285.95 | |
| 87420 | <1% | 1,241 | $285.77 | |
| 85730 | <1% | 4,874 | $277.49 | |
| 72080 | <1% | 12 | $272.30 | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 26 | $262.08 |
| 84100 | <1% | 2,334 | $247.03 | |
| 82746 | <1% | 60 | $223.63 | |
| 82962 | <1% | 7,463 | $220.66 | |
| 73620 | <1% | 256 | $210.14 | |
| 11056 | <1% | 12 | $201.52 | |
| 82550 | <1% | 755 | $200.16 | |
| G0010 | Administration of hepatitis b vaccine | <1% | 12 | $193.56 |
| 72170 | <1% | 53 | $190.40 | |
| 85007 | <1% | 1,267 | $166.63 | |
| 83020 | <1% | 68 | $157.23 | |
| 85379 | <1% | 2,351 | $151.05 | |
| 94010 | <1% | 87 | $138.98 | |
| 80076 | <1% | 54 | $113.13 | |
| 73060 | <1% | 25 | $111.32 | |
| 86039 | <1% | 36 | $89.21 | |
| 69209 | <1% | 14 | $79.36 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 172 | $66.73 |
| 87040 | <1% | 1,561 | $60.17 | |
| 76870 | <1% | 280 | $56.38 | |
| 84484 | <1% | 13,569 | $52.65 | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 53 | $50.35 |
| 86308 | <1% | 172 | $45.47 | |
| 80164 | <1% | 38 | $40.79 | |
| 84550 | <1% | 67 | $39.18 | |
| 90715 | <1% | 1,345 | $38.28 | |
| 85018 | <1% | 41 | $28.32 | |
| 87808 | <1% | 44 | $19.52 | |
| 86901 | <1% | 4,178 | $16.28 | |
| 81002 | <1% | 16 | $13.88 | |
| 87147 | <1% | 27 | $13.01 | |
| 82077 | <1% | 3,139 | $10.10 | |
| 82010 | <1% | 202 | $9.25 | |
| 82565 | <1% | 14 | $9.00 | |
| 82140 | <1% | 13 | $8.21 | |
| 83605 | <1% | 2,196 | $6.71 | |
| 83615 | <1% | 47 | $6.50 | |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 95 | $5.58 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 6,701 | $0.80 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 8,622 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 1,451 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 314 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 1,798 | $0.00 |
| 90723 | 0% | 1,382 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 1,380 | $0.00 |
| 88304 | 0% | 265 | $0.00 | |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 139 | $0.00 |
| 95886 | 0% | 880 | $0.00 | |
| 96376 | 0% | 4,154 | $0.00 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 185 | $0.00 |
| 96368 | 0% | 44 | $0.00 | |
| C1769 | Guide wire | 0% | 837 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 999 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 947 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 604 | $0.00 |
| 99417 | Prolong home eval add 15m | 0% | 41 | $0.00 |
| J3490 | Unclassified drugs | 0% | 2,543 | $0.00 |
| 94200 | 0% | 40 | $0.00 | |
| 91305 | 0% | 363 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 826 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 2,164 | $0.00 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 0% | 189 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 98 | $0.00 |
| 90698 | 0% | 105 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 26 | $0.00 |
| 90647 | 0% | 25 | $0.00 | |
| 90680 | 0% | 65 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 12 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 1,449 | $0.00 |
| C1753 | Catheter, intravascular ultrasound | 0% | 13 | $0.00 |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 0% | 13 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 49 | $0.00 |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | 0% | 39 | $0.00 |
| 88307 | 0% | 12 | $0.00 | |
| J1817 | Insulin for administration through dme (i.e., insulin pump) per 50 units | 0% | 48 | $0.00 |
| 74420 | 0% | 13 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 14 | $0.00 |
| 90696 | 0% | 25 | $0.00 | |
| Q0222 | Injection, bebtelovimab, 175 mg | 0% | 16 | $0.00 |
| 12002 | 0% | 29 | $0.00 | |
| 90681 | 0% | 685 | $0.00 | |
| 90633 | 0% | 1,041 | $0.00 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 4,954 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 14,325 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 1,381 | $0.00 |
| 87210 | 0% | 479 | $0.00 | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 0% | 773 | $0.00 |
| 94729 | 0% | 128 | $0.00 | |
| 12011 | 0% | 75 | $0.00 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 2,537 | $0.00 |
| 90685 | 0% | 189 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 468 | $0.00 |
| 90648 | 0% | 1,421 | $0.00 | |
| C1765 | Adhesion barrier | 0% | 321 | $0.00 |
| 99152 | 0% | 1,330 | $0.00 | |
| 82805 | 0% | 1,998 | $0.00 | |
| 80179 | 0% | 805 | $0.00 | |
| 90700 | 0% | 708 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 840 | $0.00 |
| 80143 | 0% | 856 | $0.00 | |
| C1758 | Catheter, ureteral | 0% | 1,253 | $0.00 |
| 90710 | 0% | 122 | $0.00 | |
| 84145 | 0% | 319 | $0.00 | |
| 90461 | 0% | 2,419 | $0.00 | |
| 82075 | 0% | 239 | $0.00 | |
| 90707 | 0% | 400 | $0.00 | |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99205, 99215, 99483 for office or other outpatient evaluation and management services) (do not report g2212 on the same date of service as 99358, 99359, 99415, 99416). (do not report g2212 for any time unit less than 15 minutes) | 0% | 26 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 287 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 376 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 163 | $0.00 |
| A4606 | Oxygen probe for use with oximeter device, replacement | 0% | 12 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 630 | $0.00 |
| 91300 | 0% | 642 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 101 | $0.00 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 213 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 33 | $0.00 |
| 90713 | 0% | 76 | $0.00 | |
| 91312 | 0% | 246 | $0.00 | |
| 76937 | 0% | 57 | $0.00 | |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | 0% | 26 | $0.00 |
| C1729 | Catheter, drainage | 0% | 49 | $0.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 78 | $0.00 |
| G0168 | Wound closure utilizing tissue adhesive(s) only | 0% | 34 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 74 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 49 | $0.00 |
| 92504 | 0% | 26 | $0.00 | |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 314 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 93 | $0.00 |
| 94150 | 0% | 39 | $0.00 | |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 25 | $0.00 |
| 93226 | 0% | 13 | $0.00 | |
| 76000 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWICKENS, JEANNE (SR VP FINANCE/CFO)
Parent organizationW.A. FOOTE MEMORIAL HOSPITAL, INC.
| Provider | Location | Paid |
|---|---|---|
| W.A. Foote Memorial Hospital, INC. | Jackson, MI | $4.90M |
| Parkview Hospital INC. | Fort Wayne, IN | $2.64M |
| Parkview Wabash Hospital, INC. | Wabash, IN | $1.20M |
| Parkview Hospital, INC. | Fort Wayne, IN | $108K |
| Healthlink, INC. | Jackson, MI | $18K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.